<DOC>
	<DOC>NCT00457743</DOC>
	<brief_summary>Phase I;To investigate the clinically recommended dose of Sunitinib malate (SU011248) following multiple oral dosing in the first cycle (4 consecutive weeks and 2 weeks rest) by reviewing the safety and tolerability. Phase II;To determine the objective tumor response and the safety of Sunitinib malate (SU011248) at the clinically recommended dose.</brief_summary>
	<brief_title>A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST)</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Patients with histologicallyconfirmed metastatic or unresectable gastrointestinal stromal tumor (GIST). Patients previously treated with imatinib mesylate. Patients who have not recovered from the acute toxic effects of previous antineoplastic therapy or treatment with imatinib mesylate. Any tumor therapy for gastrointestinal stromal tumor (GIST) discontinued less than 4 weeks prior to starting study treatment. Imatinib mesylate discontinued less than 2 weeks prior to starting therapy.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Evaluate of RTD for Japanese GIST patients</keyword>
</DOC>